

Ivan Budnik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579262/publications.pdf>

Version: 2024-02-01

45
papers

660
citations

759233

12
h-index

610901

24
g-index

45
all docs

45
docs citations

45
times ranked

923
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Factors in Deep Vein Thrombosis Initiation. Trends in Immunology, 2018, 39, 610-623.	6.8	128
2	Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitorsâ€™a single-center cohort. Pediatric Blood and Cancer, 2019, 66, e27886.	1.5	65
3	Emicizumab treatment and monitoring in a paediatric cohort: real-world data. British Journal of Haematology, 2020, 191, 282-290.	2.5	57
4	Model of trauma-induced coagulopathy including hemodilution, fibrinolysis, acidosis, and hypothermia. Journal of Trauma and Acute Care Surgery, 2017, 82, 287-292.	2.1	41
5	Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. Haemophilia, 2021, 27, 383-391.	2.1	34
6	The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thrombosis Research, 2015, 136, 465-473.	1.7	33
7	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells, Molecules, and Diseases, 2017, 65, 1-7.	1.4	30
8	Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy. Journal of Cataract and Refractive Surgery, 2011, 37, 1434-1438.	1.5	23
9	Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data. Haemophilia, 2021, 27, 253-260.	2.1	23
10	In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. Blood Transfusion, 2014, 12, 78-84.	0.4	18
11	The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model. Blood Coagulation and Fibrinolysis, 2012, 23, 370-378.	1.0	17
12	Differential Roles of Fibrinogen and von Willebrand Factor on Clot Formation and Platelet Adhesion in Reconstituted and Immune Thrombocytopenia. Anesthesia and Analgesia, 2011, 112, 1034-1040.	2.2	15
13	Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. Journal of Clinical Medicine, 2021, 10, 4303.	2.4	15
14	Thein vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia. Platelets, 2012, 23, 604-610.	2.3	12
15	Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux. International Urology and Nephrology, 2020, 52, 603-610.	1.4	10
16	Epiretinal membrane following pars plana vitrectomy for rhegmatogenous retinal detachment repair. International Journal of Ophthalmology, 2019, 12, 1872-1877.	1.1	10
17	Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator. Blood Coagulation and Fibrinolysis, 2012, 23, 729-733.	1.0	9
18	Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin-activatable fibrinolysis inhibitor. International Journal of Laboratory Hematology, 2015, 37, 521-529.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 117-127.	3.4	9
20	The potential role of emicizumab prophylaxis in severe von Willebrand disease. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102530.	1.4	9
21	Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 1-5.	1.4	8
22	Hypoxic renal injury in newborns with abdominal compartment syndrome (clinical and experimental) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	2.3	8
23	Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patientsâ€™ Lessons from Wide Genome Analyses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9074.	4.1	8
24	Synergistic effect of signaling from receptors of soluble platelet agonists and outside-in signaling in formation of a stable fibrinogen-integrin Î±IIbÎ²3-actin cytoskeleton complex. <i>Thrombosis Research</i> , 2015, 135, 114-120.	1.7	7
25	Urinary cytokines as markers of latent inflammation in children with chronic pyelonephritis and anorectal malformations. <i>Journal of Pediatric Urology</i> , 2016, 12, 153.e1-153.e6.	1.1	7
26	Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1927-1932.	3.4	7
27	Correlation between Interleukin-6 and Thrombinâ€™Antithrombin III Complex Levels in Retinal Diseases. <i>Current Eye Research</i> , 2017, 42, 1269-1272.	1.5	6
28	Activated protein C induces suppression and regression of choroidal neovascularizationâ€™ A murine model. <i>Experimental Eye Research</i> , 2019, 186, 107695.	2.6	6
29	Role of G protein signaling in the formation of the fibrin(ogen)â€™integrin Î±IIbÎ²3â€™actin cytoskeleton complex in platelets. <i>Platelets</i> , 2016, 27, 563-575.	2.3	5
30	Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction. <i>Biomolecules</i> , 2021, 11, 358.	4.0	5
31	The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. <i>Experimental and Molecular Pathology</i> , 2020, 116, 104524.	2.1	4
32	Role of heterotrimeric G proteins in platelet activation and clot formation in platelets treated with integrin Î±IIbÎ²3 inhibitor. <i>Platelets</i> , 2018, 29, 265-269.	2.3	3
33	Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry. <i>Pathophysiology</i> , 2018, 25, 347-351.	2.2	3
34	In-vitro assessment of the effects of fibrinogen, recombinant factor VIIa and factor XIII on trauma-induced coagulopathy. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 253-257.	1.0	3
35	EXPERIMENTAL AND CLINICAL RATIONAL FOR TERAHERTZ THERAPY AT THE FREQUENCY OF MOLECULAR OXYGEN AND NITROGEN OXIDE ABSORPTION AND EMISSION IN DIFFERENT PATHOLOGIES. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2017, 72, 365-374.	0.6	3
36	Effect of Subretinal Fluid Drainage Using Perfluorocarbon During Retinal Detachment Repair on Postoperative Metamorphopsia. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, e263-e270.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 95, 102663.	1.4	3
38	Thromboelastometry assessment of the effects of fibrinogen, activated prothrombin complex concentrate, and tranexamic acid on clot formation and fibrinolysis in a model of trauma-induced coagulopathy. <i>European Journal of Trauma and Emergency Surgery</i> , 2021, 47, 1057-1063.	1.7	2
39	Pediatric severe factor XI deficiency: A multicenter study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29545.	1.5	2
40	Reflux nephropathy in children: early diagnosis and monitoring. <i>Urologiia</i> , 2017, 4_2017, 107-112.	0.2	0
41	Intra-abdominal Hypertension Syndrome in Children. <i>Novosti Khirurgii</i> , 2017, 25, 621-631.	0.2	0
42	Effects of fibrinogen concentrate, factor XIII, and thrombin-activatable fibrinolysis inhibitor on clot firmness and fibrinolytic resistance in the model of hyperfibrinolysis. <i>Patologicheskaiia Fiziologiiia i Eksperimental'naia Terapiia</i> , 2017, , 44-50.	0.1	0
43	Role of interleukin-10 and interleukin-24 in the pathogenesis of D^{b} -cell chronic lymphocytic leukemia. <i>Nauchno-prakticheskii Zhurnal "Patogenez"</i> , 2018, , 56-61.	0.2	0
44	Improving clot formation with a combination of fibrinogen concentrate and activated prothrombin complex concentrate in a model of severe thrombocytopenia. <i>Nauchno-prakticheskii Zhurnal "Patogenez"</i> , 2018, , 23-29.	0.2	0
45	Activated Protein C Induces Stabilization of the Outer Retinal Barrier and Inhibits Laser Induced Choroidal Neovascularization in a Murine Model. <i>Blood</i> , 2018, 132, 73-73.	1.4	0